+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A novel FGFR1-binding peptide exhibits anti-tumor effect on lung cancer by inhibiting proliferation and angiogenesis



A novel FGFR1-binding peptide exhibits anti-tumor effect on lung cancer by inhibiting proliferation and angiogenesis



International Journal of Biological Sciences 14(10): 1389-1398



It has been reported that overactivation of fibroblast growth factor receptor 1 (FGFR1) is an important characteristic found in most non-small cell lung cancer (NSCLC) samples. Here, we identified a FGFR1 inhibitory peptide R1-P2 and investigated its effects on the lung cancer cells growth and angiogenesis in vitro and in vivo. Our results demonstrate that R1-P2 bound to human FGFR1 protein, and efficiently blocked the binding of FGF2 to FGFR1 in A549 and NCI-H460 cells. Moreover, this peptide significantly decreased the proliferation, migration and invasion, but promoted the apoptosis in both cell lines. In addition, R1-P2 treatment effectively inhibited the tumor growth and neovascularization in nude mice with xenografted A549 cells, and R1-P2 also significantly inhibited the FGF2-induced angiogenesis in tube formation experiment and CAM model. We further demonstrated that R1-P2 suppressed lung tumor growth through anti-angiogenic and anti-proliferative activity. Our data may provide a novle leading molecule with potential application in the treatment of FGFR1 activation related lung cancers.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048009886

Download citation: RISBibTeXText

PMID: 30123084

DOI: 10.7150/ijbs.24739


Related references

Effect of inhibiting tumor angiogenesis on cell proliferation and apoptosis in mice with bladder cancer. Journal of China Medical University 32(2): 148-150, 2003

PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis. Biochemical Pharmacology, 2018

PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis. Biochemical Pharmacology 150: 131-140, 2018

CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models. Lung Cancer (): -, 2016

Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase. Journal of Biological Chemistry 286(4): 2681-2688, 2011

Peroxisome proliferator-activated receptor-gamma agonists impede tumor growth in non-small cell lung cancer by inhibiting cell proliferation and angiogenesis. Proceedings of the American Association for Cancer Research Annual Meeting 44: 466, July, 2003

CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis. Oncotarget 6(25): 21315-21327, 2016

2-Naphthoic acid ergosterol ester, an ergosterol derivative, exhibits anti-tumor activity by promoting apoptosis and inhibiting angiogenesis. Steroids 122: 9-15, 2017

Assessment of FGFR1 Overexpression and Over-Activity in Lung Cancer Cells: A Toolkit for Anti-FGFR1 Drug Screening. Human Gene Therapy Methods, 2017

Mountain ginseng extract exhibits anti-lung cancer activity by inhibiting the nuclear translocation of NF-κB. American Journal of Chinese Medicine 40(1): 187-202, 2012

Grifolin exhibits anti-cancer activity by inhibiting the development and invasion of gastric tumor cells. Oncotarget 8(13): 21454-21460, 2017

Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Research 68(6): 2043-2050, 2008

Catalpol suppressed proliferation, growth and invasion of CT26 colon cancer by inhibiting inflammation and tumor angiogenesis. Biomedicine & PharmacoTherapy 95: 68-76, 2017

Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis. Current Cancer Drug Targets 14(6): 557-566, 2015

Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum. Oncology Letters 10(1): 137-142, 2015